drug
Entia
Marketedupdated 6mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval16 co-mentions · 8 sources
- drugXalox9 co-mentions · 9 sources
- drugOXALIPLATIN9 co-mentions · 9 sources
- tagOncology2 co-mentions · 1 sources
- drugFLUOROURACIL1 co-mentions · 1 sources
- drugEfudex1 co-mentions · 1 sources
- drugFAVLYXA1 co-mentions · 1 sources
- companyTehran University of Medical Sciences1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Entia
- phase3Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- phase2A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- phase3RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
- phase2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase3A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- phase1A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- phase2Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
News(2)
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”biopharma_dive · 5mo ago
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 6mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that